FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286294074> ?p ?o ?g. }

• W4286294074 endingPage "7572" @default.
• W4286294074 startingPage "7572" @default.
• W4286294074 abstract "7572 Background: Tazemetostat (TAZ), an enhancer of zeste homolog 2 (EZH2) inhibitor, showed antitumor activity as monotherapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL) who received ≥2 prior lines of therapy. In clinical studies in patients with R/R FL, lenalidomide and rituximab (R 2 ) demonstrated an objective response rate (ORR) of 73%–78% and median progression-free survival (PFS) of 36–39 months. This global, multicenter phase 1b/3 study is designed to determine the recommended phase 3 dose (RP3D), efficacy, and safety of TAZ + R 2 in patients with R/R FL after ≥1 prior therapy. We report an updated interim analysis of the phase 1b safety run-in where we assess the clinical activity and pharmacokinetics (PK) of TAZ when administered with R 2 in patients with R/R FL. Methods: Phase 1b evaluated TAZ at 3 dose levels (400, 600, and 800 mg orally twice daily) in 28-day cycles with standard-dose R 2 (NCT04224493). In addition to PK and safety, preliminary efficacy analysis was performed on the response-evaluable population, including best overall response, PFS, and duration of response (DOR) per investigator assessment according to Lugano 2014 response criteria. Results: As of January 22, 2022, 43 patients were enrolled and receiving TAZ + R 2 (400 [n = 4], 600 [n = 18], and 800 mg [n = 21]). These patients had a median age of 67 years (range, 39–83) and received a median of 1 prior therapy (range, 1–4). Overall, 15/43 (34.9%) patients were refractory to rituximab, 10/39 (25.6%) had POD24, and 6/41 (14.6%) had mutant-type EZH2. Median duration of treatment exposure was 32.0 weeks (range, 4.1–68.1). Mean C max and AUC 0–t of TAZ 800 mg + R 2 at steady state were similar to those found for TAZ as monotherapy. PK of TAZ was not altered by concomitant administration of daily oral lenalidomide 20 mg, and PK of lenalidomide was not altered by concomitant administration of TAZ. No dose-limiting toxicities were observed in phase 1b, and no new safety signals were identified as of the January 2022 data cutoff. Serious treatment-emergent adverse events (TEAEs) were observed in 14 (32.6%) patients. Grade 3–4 TEAEs were observed in 24 (55.8%) patients; the most common grade 3–4 TEAE was neutrophil count decrease (n = 13; 30.2%). Of 38 patients evaluable for tumor assessment, 19 (50.0%) had a complete response, 17 (44.7%) had a partial response, and 2 (5.3%) had stable disease. ORR was 94.7% (n = 36). With a median follow-up of 5.8 months, median PFS and DOR were not reached and appeared to be similar, regardless of mutation status. Conclusions: TAZ + R 2 combination demonstrates consistent and unaltered PK for TAZ and lenalidomide as well as a favorable safety profile and efficacy trend. The 2-arm randomized phase 3 portion will further explore the efficacy and safety of TAZ RP3D 800 mg + R 2 in ≈500 patients with R/R FL. Clinical trial information: NCT04224493." @default.
• W4286294074 created "2022-07-21" @default.
• W4286294074 creator A5004717644 @default.
• W4286294074 creator A5027520603 @default.
• W4286294074 creator A5031776733 @default.
• W4286294074 creator A5034090582 @default.
• W4286294074 creator A5037882455 @default.
• W4286294074 creator A5045105562 @default.
• W4286294074 creator A5045676616 @default.
• W4286294074 creator A5051605599 @default.
• W4286294074 creator A5062534813 @default.
• W4286294074 creator A5063078317 @default.
• W4286294074 creator A5073297836 @default.
• W4286294074 creator A5075692970 @default.
• W4286294074 creator A5080271939 @default.
• W4286294074 creator A5080443755 @default.
• W4286294074 date "2022-06-01" @default.
• W4286294074 modified "2023-10-07" @default.
• W4286294074 title "Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma." @default.
• W4286294074 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.7572" @default.
• W4286294074 hasPublicationYear "2022" @default.
• W4286294074 type Work @default.
• W4286294074 citedByCount "2" @default.
• W4286294074 countsByYear W42862940742023 @default.
• W4286294074 crossrefType "journal-article" @default.
• W4286294074 hasAuthorship W4286294074A5004717644 @default.
• W4286294074 hasAuthorship W4286294074A5027520603 @default.
• W4286294074 hasAuthorship W4286294074A5031776733 @default.
• W4286294074 hasAuthorship W4286294074A5034090582 @default.
• W4286294074 hasAuthorship W4286294074A5037882455 @default.
• W4286294074 hasAuthorship W4286294074A5045105562 @default.
• W4286294074 hasAuthorship W4286294074A5045676616 @default.
• W4286294074 hasAuthorship W4286294074A5051605599 @default.
• W4286294074 hasAuthorship W4286294074A5062534813 @default.
• W4286294074 hasAuthorship W4286294074A5063078317 @default.
• W4286294074 hasAuthorship W4286294074A5073297836 @default.
• W4286294074 hasAuthorship W4286294074A5075692970 @default.
• W4286294074 hasAuthorship W4286294074A5080271939 @default.
• W4286294074 hasAuthorship W4286294074A5080443755 @default.
• W4286294074 hasConcept C112705442 @default.
• W4286294074 hasConcept C121332964 @default.
• W4286294074 hasConcept C126322002 @default.
• W4286294074 hasConcept C142424586 @default.
• W4286294074 hasConcept C143998085 @default.
• W4286294074 hasConcept C197934379 @default.
• W4286294074 hasConcept C2776063141 @default.
• W4286294074 hasConcept C2776364478 @default.
• W4286294074 hasConcept C2776694085 @default.
• W4286294074 hasConcept C2777058707 @default.
• W4286294074 hasConcept C2777063308 @default.
• W4286294074 hasConcept C2778375690 @default.
• W4286294074 hasConcept C2779338263 @default.
• W4286294074 hasConcept C2780653079 @default.
• W4286294074 hasConcept C2908647359 @default.
• W4286294074 hasConcept C31760486 @default.
• W4286294074 hasConcept C535046627 @default.
• W4286294074 hasConcept C61943457 @default.
• W4286294074 hasConcept C71924100 @default.
• W4286294074 hasConcept C87355193 @default.
• W4286294074 hasConcept C90924648 @default.
• W4286294074 hasConcept C99454951 @default.
• W4286294074 hasConceptScore W4286294074C112705442 @default.
• W4286294074 hasConceptScore W4286294074C121332964 @default.
• W4286294074 hasConceptScore W4286294074C126322002 @default.
• W4286294074 hasConceptScore W4286294074C142424586 @default.
• W4286294074 hasConceptScore W4286294074C143998085 @default.
• W4286294074 hasConceptScore W4286294074C197934379 @default.
• W4286294074 hasConceptScore W4286294074C2776063141 @default.
• W4286294074 hasConceptScore W4286294074C2776364478 @default.
• W4286294074 hasConceptScore W4286294074C2776694085 @default.
• W4286294074 hasConceptScore W4286294074C2777058707 @default.
• W4286294074 hasConceptScore W4286294074C2777063308 @default.
• W4286294074 hasConceptScore W4286294074C2778375690 @default.
• W4286294074 hasConceptScore W4286294074C2779338263 @default.
• W4286294074 hasConceptScore W4286294074C2780653079 @default.
• W4286294074 hasConceptScore W4286294074C2908647359 @default.
• W4286294074 hasConceptScore W4286294074C31760486 @default.
• W4286294074 hasConceptScore W4286294074C535046627 @default.
• W4286294074 hasConceptScore W4286294074C61943457 @default.
• W4286294074 hasConceptScore W4286294074C71924100 @default.
• W4286294074 hasConceptScore W4286294074C87355193 @default.
• W4286294074 hasConceptScore W4286294074C90924648 @default.
• W4286294074 hasConceptScore W4286294074C99454951 @default.
• W4286294074 hasIssue "16_suppl" @default.
• W4286294074 hasLocation W42862940741 @default.
• W4286294074 hasOpenAccess W4286294074 @default.
• W4286294074 hasPrimaryLocation W42862940741 @default.
• W4286294074 hasRelatedWork W2126113018 @default.
• W4286294074 hasRelatedWork W2126772526 @default.
• W4286294074 hasRelatedWork W2928264246 @default.
• W4286294074 hasRelatedWork W2979596396 @default.
• W4286294074 hasRelatedWork W3209145154 @default.
• W4286294074 hasRelatedWork W3210051517 @default.
• W4286294074 hasRelatedWork W3211871624 @default.
• W4286294074 hasRelatedWork W3216465163 @default.
• W4286294074 hasRelatedWork W4212971766 @default.
• W4286294074 hasRelatedWork W4296533012 @default.
• W4286294074 hasVolume "40" @default.

• next